Recombinant PTH(1-84)

Natpara is the complete 84-residue human parathyroid hormone made in E. coli, biologically identical to the endogenous hormone. It binds the PTH1 receptor in kidney and bone, increasing distal tubular calcium reabsorption, reducing tubular phosphate reabsorption, and stimulating renal 1-alpha-hydroxylase to convert 25-hydroxyvitamin D into its active 1,25-dihydroxy form, which in turn raises intestinal calcium absorption. In chronic hypoparathyroidism, treating with calcium and calcitriol alone corrects serum calcium but leaves urinary calcium high and the kidneys at long-term risk; replacing the hormone itself addresses the actual deficiency. In the REPLACE trial roughly half the patients on Natpara achieved normal serum calcium while cutting calcium and active vitamin D by at least half. Takeda discontinued it globally at the end of 2024 after persistent manufacturing problems with rubber particulate in the cartridges, not because of any efficacy failure.

Targets: PTH1 receptor, Renal distal tubular calcium reabsorption, Renal 1-alpha-hydroxylase, Urinary phosphate excretion

• · Start 50 mcg once daily and adjust in 25 mcg steps every 4 weeks between 25 and 100 mcg. Active vitamin D was halved at initiation if serum calcium was above 7.5 mg/dL.

Work out your exact syringe units →

• very commonHypercalcaemia— Most often during titration, when calcium and calcitriol were not reduced fast enough.
• very commonHypocalcaemia— Especially on missed doses or interruption; this is the reason for the risk-management programme it carried.
• commonParaesthesia, muscle spasm and tingling— Usually reflects the calcium level rather than a direct effect.
• commonNausea, headache and diarrhoea
• commonHypercalciuria
• rareOsteosarcoma risk in rats— Carried a boxed warning based on rodent data, restricting use to a REMS programme. No human cases were attributed to it.

• Historically restricted to patients who could not be well controlled on calcium and active vitamin D alone
• Prior skeletal radiation therapy
• Paget's disease or unexplained elevated alkaline phosphatase
• Bone metastases or skeletal malignancy
• Hereditary osteosarcoma predisposition
• No longer commercially available anywhere as of 2025

• redundantpalopegteriparatide — Yorvipath is the successor product for the same indication and is what former Natpara patients were transitioned to.
• redundantteriparatide — Teriparatide was used off-label twice daily as a bridge for some patients during the Natpara withdrawal.
• conflictetelcalcetide — Diametrically opposed goals on the PTH axis.

• · Albumin-corrected serum calcium before each dose change and periodically after
• · 24-hour urinary calcium
• · Serum phosphate and magnesium
• · Renal imaging for nephrocalcinosis over years
• · 25-hydroxyvitamin D

Discontinued worldwide as of the end of 2024. Included here because it defined the treatment category and because the literature and clinical reasoning around it still matter.

• Natpara FDA prescribing information, including the boxed osteosarcoma warning (label)
• Mannstadt et al. 2013 Lancet Diabetes and Endocrinology, REPLACE trial of recombinant human PTH(1-84) in hypoparathyroidism (trial)
• Takeda 2024 announcement of global discontinuation of Natpara and Natpar (other)

Natpara was the first attempt at true hormone replacement in hypoparathyroidism, and it failed pharmacokinetically rather than pharmacologically. PTH1R signalling in the distal tubule increases calcium reabsorption, in the proximal tubule reduces phosphate reabsorption, and via 1-alpha-hydroxylase converts 25-hydroxyvitamin D to its active form, raising intestinal calcium absorption. All three arms are what conventional calcium and calcitriol therapy fails to reproduce: that regimen normalises serum calcium by pushing a large filtered load through a kidney with no PTH-driven reabsorption, so urinary calcium stays high, and nephrocalcinosis and chronic kidney disease follow over decades. Replacing the hormone addresses the actual deficiency. The problem was exposure shape. A 3 hour half-life delivered once daily gives an early peak and then a long tail, so patients experienced a calcium excursion after each injection and a trough before the next, which is why many needed twice-daily dosing off-label and why only about half achieved the REPLACE composite endpoint. The full-length molecule also carries a C-terminal region with its own biology, including proposed signalling at a distinct C-terminal PTH receptor on osteocytes that may oppose PTH1R-driven resorption, which is a theoretical argument for PTH(1-84) over PTH(1-34) that was never resolved clinically. The product's withdrawal at the end of 2024 was a manufacturing failure, rubber particulate in the cartridges, not an efficacy or safety failure, and thousands of patients had to be transitioned off a hormone they were dependent on, which is a case study in what happens when a single-source orphan biologic fails.

The defining problem was the exposure profile: once-daily dosing of a 3 hour half-life hormone produced a peak and then a trough, so patients oscillated rather than sitting in a steady state, and a meaningful proportion needed twice-daily dosing that was never in the label. That is why only about half achieved the REPLACE endpoint. The second problem was interruption: missed doses produced severe hypocalcaemia, which is why the product carried a risk-management programme, and why abrupt discontinuation was genuinely dangerous. The third was the boxed osteosarcoma warning based on rodent data, which restricted use through a REMS programme and which, as with teriparatide and abaloparatide, was never borne out in humans. The fourth, and the one that actually ended the product, was manufacturing: rubber particulate in the dual-chamber cartridges led to recalls and eventually to global discontinuation at the end of 2024. That is a specific and underappreciated risk of single-source orphan biologics, and patients dependent on a hormone had weeks to find an alternative. Anyone reading this record should understand that the drug is not available anywhere and this entry exists because it defined the category and because the clinical reasoning still applies.

1. 50 mcgWeek 1, historical regimen — 50 mcg subcutaneously once daily into the thigh, alternating sides. Active vitamin D was halved at initiation if serum calcium was above 7.5 mg/dL.
2. 75 mcgWeek 5 onward — Adjust in 25 mcg steps no more often than every 4 weeks, guided by albumin-corrected serum calcium. Active vitamin D was withdrawn first, then calcium supplementation was tapered.
3. 100 mcgUpper dose — 100 mcg once daily was the maximum. Licensed range was 25 to 100 mcg.
4. 25 mcgLower dose — 25 mcg once daily was the minimum, used where the response was strong or residual parathyroid function existed.
5. —Discontinuation — Never stopped abruptly. Any interruption required immediate reinstatement of calcium and active vitamin D, which is exactly the transition thousands of patients had to make when the product was withdrawn at the end of 2024.

• PTH1 receptor in renal distal tubule — Native ligand affinity; numeric values not resolved this session.

  Increased calcium reabsorption, which is the arm that distinguishes hormone replacement from calcium supplementation.

• PTH1 receptor in renal proximal tubule — Native

  Reduced phosphate reabsorption, correcting hyperphosphataemia, and stimulation of 1-alpha-hydroxylase restoring endogenous 1,25-dihydroxyvitamin D production.

• PTH1 receptor on osteoblasts and osteocytes — Native

  Once-daily rather than continuous exposure gave a partly pulsatile signal, so bone turnover rose from the abnormally suppressed baseline of untreated hypoparathyroidism. That is expected, not harmful, though it produces a bone mineral density fall that alarms people who have not been warned.

• Proposed C-terminal PTH receptor on osteocytes — Poorly characterised

  Hypothesised to oppose PTH1R-driven resorption. This was the theoretical argument for full-length PTH over the 1-34 fragment, and it was never settled.

• REPLACE Phase 3, double-blind, placebo-controlled, randomised · 24 weeks · 2013

  Composite endpoint of at least 50 percent reduction in both oral calcium and active vitamin D dose while maintaining or normalising serum calcium. Roughly half of treated patients achieved it against a very small minority on placebo, which established PTH replacement as a viable strategy while also showing it was far from universally successful.

Serum calcium rose within hours of a dose. Reduction in calcium and active vitamin D requirements took weeks of stepwise adjustment at 4-week intervals. Bone turnover markers rose from the abnormally suppressed baseline over months, with a corresponding bone mineral density fall that reflects normalisation rather than harm. Renal outcomes, the reason for the whole strategy, would only manifest over years, and the product was withdrawn before that question was answered.

As with palopegteriparatide, the stack was defined by what came off rather than what went on: active vitamin D withdrawn first, then supplemental calcium tapered, with plain vitamin D continuing as substrate. Thiazides, frequently used in hypoparathyroidism specifically to reduce hypercalciuria, often became unnecessary. Digoxin required care because of the calcium swings. Magnesium repletion was a prerequisite. Teriparatide given twice daily off-label was used as a bridge by many patients during the withdrawal, which was pharmacologically crude but available. It was never combined with etelcalcetide or any calcimimetic, which pull the PTH axis in the opposite direction.

Against palopegteriparatide: this is the comparison that matters, and it is decisive. Yorvipath's TransCon linker releases PTH(1-34) continuously with a 60-hour effective half-life, producing genuine 24-hour replacement, and in the PaTHway trial the large majority of patients came off conventional therapy entirely, against roughly half in REPLACE. Natpara had the better molecule, full-length PTH with its C-terminal biology intact, and the worse kinetics, and kinetics won. Against conventional calcium plus calcitriol: cheap, universally available, and adequate for serum calcium, but it leaves urinary calcium high and the kidneys at long-term risk, which is what hormone replacement was meant to fix. Against off-label twice-daily teriparatide: available and inexpensive, but two injections a day and still not continuous. The withdrawal of Natpara at the end of 2024, coinciding with the approval of Yorvipath, meant the category was replaced rather than abandoned, which is fortunate timing that should not be mistaken for planning.

Not applicable. Discontinued worldwide as of the end of 2024. When marketed it carried orphan-drug pricing in the tens of thousands of dollars per year.

• ?Bioavailability of 53 percent and a 1 to 2 hour tmax are commonly reported figures for Natpara that I did not resolve against a label in this session, since the product has been withdrawn and its label is no longer maintained. Treat both as approximate.
• ?Volume of distribution, clearance and protein binding were not resolved.
• ?The 84-residue sequence is not given in one-letter form because I did not resolve it from a primary source this session.
• ?REPLACE's enrolment was not confirmed against the paper, so participants is null; it was in the region of 130 patients.
• ?Whether the C-terminal region of PTH(1-84) confers any clinical advantage over PTH(1-34) was never resolved and now probably never will be.
• ?The rodent osteosarcoma signal that generated the boxed warning was never observed in humans, consistent with the experience with teriparatide and abaloparatide whose warnings were removed in 2021.

• Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study Mannstadt M, et al., Lancet Diabetes & Endocrinology, 2013 · PMID 24622413

  The registration trial. Read the response rate honestly: about half the patients achieved the composite endpoint, which is a long way from the near-universal independence from conventional therapy that palopegteriparatide later demonstrated.